By: Cat Duffy and Liz McCaman Taylor
Executive Summary
The U.S. Food and Drug Administration (FDA) announced new changes to the mifepristone Risk Evaluation and Mitigation Strategy (REMS) in January 2023, opening the door to the expansion of medication abortion access through pharmacist dispensing. However, equitable abortion access under this model requires intentional benefit design in order to ensure insurance coverage at the pharmacy counter. This FAQ goes through the key concepts and issues surrounding pharmacist-dispensed medication abortion, including the policy changes that are required to facilitate insurance coverage in both public and private plans.
